Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders

Neuropsychopharmacology

Volumn 35, Issue 4, 2010, Pages 990-998

  Hollander, Eric ^a   Chaplin, William ^b   Soorya, Latha ^c   Wasserman, Stacey ^c   Novotny, Sherry ^c   Rusoff, Jade ^c   Feirsen, Nicole ^c   Pepa, Lauren ^c   Anagnostou, Evdokia ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ST JOHN'S UNIVERSITY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adolescents; ASD; Children; Divalproex; Irritability

Indexed keywords

PLACEBO; VALPROATE SEMISODIUM;

ADOLESCENT; AGGRESSION; AGITATION; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; INTELLIGENCE QUOTIENT; IRRITABILITY; MALE; POLYURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; VIRUS INFECTION; WEIGHT GAIN;

ADOLESCENT; ANTIMANIC AGENTS; CHILD; CHILD BEHAVIOR DISORDERS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IRRITABLE MOOD; MALE; PERSONALITY ASSESSMENT; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME; VALPROIC ACID;

EID: 76749085678     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.202     Document Type: Article

References (42)

1. Allen MH, Hirschfeld RM, Wozniak PJ, Baker JD, Bowden CL (2006). Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 163: 272-275.
2. Aman M, Singh N, Stewart A, Field C (1985). The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89: 485-491.
3. Aman MG (2004). Management of hyperactivity and other acting-out problems in patients with ASD spectrum disorder. Semin Pediatr Neurol 11: 225-228.
4. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR, 4th edn. American Psychiatric Association: Washington, DC.
5. Amiet C, Gourfinkel-An I, Bouzamondo A, Tordjman S, Baulac M, Lechat P et al (2008). Epilepsy in autism is associated with intellectual disability and gender: evidence from a meta-analysis. Biol Psychiatry 64: 577-582.
6. Belsito KM, Law PA, Kirk KS, Landa RJ, Zimmerman AW (2001). Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. Journal of ASD and Developmental Disorders 31: 175-181.
7. Bjork JM, Moeller FG, Kramer GL, Kram M, Suris A, Rush AJ et al (2001). Plasma GABA levels correlate with aggressiveness in relatives of patients with unipolar depressive disorder. Psychiatry Res 101: 131-136.
8. Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry 62: 239-248.
9. Casanova MF, Buxhoeveden D, Gomez J (2003). Disruption in the inhibitory architecture of the cell minicolumn: implications for ASD. Neuroscientist 9: 496-507.
10. Chen G, Huang LD, Jiang YM, Manji HK (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 72: 1327-1330.
11. Coccaro E, Harvey P, Kupsaw L, Herbert J, Herbert JL, Bernstein DP (1991). Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci 3: S44-S51.
12. Craft M, Ismail IA, Krishnamurti D, Mathews J, Regan A, Seth RV et al (1987). Lithium in the treatment of aggression in mentally handicapped patients: a double blind trial. Br J Psychiatry 150: 685-689.
13. Damore J, Stine J, Brody L (1998). Medication-induced hypomania in Asperger's disorder. J Am Acad Child Adolesc Psychiatry 37: 248-249.
14. Donovan SJ, Susser ES, Nunes EV, Stewart JW, Quitkin FM, Klein DF (1997). Divalproex treatment of disruptive adolescents: a report of 10 cases. J Clin Psychiatry 58: 12-15.
15. Göttlicher M (2004). Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Annu Hematol 83(Suppl 1): S91-S92.
16. Guy W (1976). ECDEU Assessment Manual for Psychopharmaco-logy. Revised. NIMH Publication DHEW Publ No (adm.) 76-388. National Institute of Mental Health: Bethesda, MD, 217-222.
17. Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM et al (2005). A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15: 682-692.
18. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S (2001). An open trial of divalproex sodium in ASD spectrum disorders. J Clin Psychiatry 62: 530-534.
19. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P et al (2003). Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuro-psychopharmacology 28: 1186-1197.
20. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 162: 621-624.
21. Jesner OS, Aref-Adib M, Coren E (2007). Risperidone for ASD spectrum disorder. Cochrane Database Syst Rev (1). Art. No. CD005040.
22. Kastner T, Finesmith R, Walsh K (1993). Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 13: 448-451.
23. Kerbeshian J, Burd L, Fisher W (1987). Lithium carbonate in the treatment of two patients with infantile ASD and atypical bipolar symptomatology. J Clin Psychopharmacol 7: 401-405.
24. Lord C, Rutter M, DiLavre PC (1998). ASD Diagnostic Observation Schedule-Generic (ADOS-G). Psychological Corp: San Antonio, TX.
25. Manji HK, Chen G (2000). Post-receptor signaling pathways in the pathophysiology and treatment of mood disorders. Curr Psychiatry Rep 2: 479-489.
26. Mattes JA (1992). Valproic acid for nonaffective aggression in the mentally retarded. J Nerv Ment Dis 180: 601-602.
27. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG et al (2002). Research units on pediatric psychopharmacology autism network. Risperidone in children with autism and serious behavioral problems. Engl J Med 347: 314-321.
28. McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ et al (1995). A case-controlled study of repetitive thoughts and behaviors in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 152: 772-777.
29. Roid GH, Miller LJ (1995;1997). Leiter International Performance Scale-Revised. Stoelting Co.: Wood Dale, Il.
30. Rutter M, Lord C, LeCouteur A (1994). ASD Diagnostic Interview-Revised (ADI-R), 3rd edn. Department of Psychiatry: University of Chicago.
31. Soderpalm B (2002). Antivonvulsants: aspects of their mechanism of action. Eur J Pain 6(suppl A): 3-9.
32. Sovner R (1989). The use of valproate in the treatment of mentally retarded persons with typical and atypical bipolar disorders. J Clin Psychiatry 50: 40-43.
33. Sparrow S, Balla D, Cicchetti DV (1984). Vineland Adaptive Behavior Scales (Survey Form). American Guidance Service: Circle Pines, MN.
34. Stoll AL, Banov M, Kolbrener M, Mayer PV, Tohen M, Strakowski SM (1994). Neurologic factors predict a favorable valproate response in bipolar and schizoaffective disorders. J Clin Psycho-pharmacol 14: 311-313.
35. Szyf M (2009). Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 49: 243-263.
36. Teingard R, Biederman J (1987). Lithium, responsive manic-like symptoms in two individuals with ASD and mental retardation. J Am Acad Child Adolesc Psychiatry 26: 932-935.
37. Vebrant P, Bauziene R (1994). Intractable epilepsy in children. The efficacy of lamotrigine treatment including non-seizure-related benefits. Neuropediatrics 25: 284-289.
38. Wasserman S, Iyengar R, Chaplin WF, Watner D, Waldoks SE, Anagnostou E (2006). Levetiracetam versus placebo in childhood and adolescent ASD: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 21: 363-367.
39. Williams SK, Scahill L, Vitiello B, Aman MG, Arnold LE, McDougle CJ et al (2006). Risperidone and adaptive behavior in children with ASD. J Am Acad Child Adolesc Psychiatry 45: 431-439.
40. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang DM (2009). The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14: 51-59.
41. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 133: 429-435.
42. Youngstrom EA, Gracious BL, Danielson CK, Findling RL, Calabrese J (2003). Toward an integration of parent and clinician report on the Young Mania Rating Scale. J Affect Disord 77: 179-190.